Influvac Tetra

Influenza virus vaccine, quadrivalent, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It induces active immunity to prevent influenza caused by the B/Phuket/3073/2013-like and B/Austria/1359417/202-like virus strains in individuals recommended for seasonal flu vaccination, including adults and children as defined by public health guidelines.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Influvac Tetra is a quadrivalent influenza vaccine used to prevent influenza infection caused by specific B virus strains. - Influenza B/Phuket/3073/2013-like virus: prevention of seasonal influenza caused by this strain. - Influenza B/Austria/1359417/202-like virus: prevention of seasonal influenza caused by this strain. - Seasonal influenza (broad protection): reduction of disease incidence and complications from circulating influenza viruses covered by the quadrivalent formulation.

Common side effects are generally mild and transient.

Common Side Effects: - Injection site pain: mild soreness at the injection site. - Redness: localized erythema around the injection area. - Swelling: temporary edema at the site. - Fever: low‑grade temperature rise within 24 hours. - Headache: mild to moderate headache post‑vaccination. - Myalgia: muscle aches lasting a day or two.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported after influenza vaccination. - Seizures: infrequent occurrence, especially in children with fever. - High fever: temperature above 39 °C persisting beyond 48 hours. - Severe allergic reaction: urticaria, angioedema, or respiratory distress. - Thrombocytopenia: rare drop in platelet count.

Vaccination should be considered with attention to individual health status. - Allergy history: avoid in persons with severe hypersensitivity to any vaccine component. - Acute illness: postpone vaccination if the individual has moderate or severe feverish illness. - Observation: monitor the patient for at least 15 minutes after injection for immediate reactions. - Egg protein sensitivity: assess risk if the vaccine contains residual egg proteins. - Pregnancy and lactation: consult a healthcare professional; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other medical products that affect immune response.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks. - Immunoglobulin therapy: may diminish vaccine efficacy if given concurrently. - Blood products: can interfere with immune response when administered close to vaccination.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: may reduce antibody production, monitor serologic response. - Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever. - Corticosteroids: high‑dose therapy could attenuate immune response.